10x Genomics vs Beam Therapeutics
Side-by-side comparison of AI visibility scores, market position, and capabilities
Leading single-cell genomics platform; $642M FY2025 revenue. Chromium and Visium spatial platforms power cell-type discovery in oncology, neuroscience, and immunology.
About
10x Genomics was founded in 2012 in Pleasanton, California by Serge Saxonov, Ben Hindson, and Kevin Ness. The company developed the Chromium platform for single-cell RNA sequencing (scRNA-seq), enabling researchers to analyze gene expression across thousands of individual cells simultaneously—a capability that transformed cell biology, immunology, and cancer research. The Visium Spatial Gene Expression platform extended this to map gene expression within intact tissue architecture.\n\n10x Genomics' instruments and consumables are used by leading academic research centers, pharmaceutical companies, and translational medicine teams to profile the cellular composition of tumors, map the nervous system, characterize immune responses, and develop cell therapies. The company reported full-year 2025 revenue of $642.8 million, up from $610.8 million in 2024, and guides to $600–$625 million for 2026 amid cautious biotech funding conditions.\n\nThe company is transitioning toward a broader multi-omics portfolio including ATAC-seq, protein detection, and spatial multi-omics, while defending market position against competition from Parse Biosciences, Vizgen, and others. Despite near-term funding headwinds in academic markets, 10x Genomics remains a foundational infrastructure provider for the cell atlas era of biology.
Beam Therapeutics develops precision genetic medicines using base editing technology that makes single-letter DNA changes without cutting the double helix.
About
Beam Therapeutics is a genetic medicines company founded in 2017 by base editing pioneers David Liu, J. Keith Joung, and Feng Zhang, having raised over $600M and gone public on Nasdaq. The company is built around base editing, a technology that makes precise single nucleotide changes in DNA without creating double-strand breaks, reducing the risk of unintended insertions or deletions compared to traditional CRISPR. Beam is developing a portfolio of base editing medicines targeting blood disorders, liver diseases, and immuno-oncology, including sickle cell disease, beta-thalassemia, and various cancers. The company also employs prime editing, a newer and even more precise gene editing modality for more complex genetic changes. Beam's pipeline includes both in vivo therapies delivered directly into the body and ex vivo cell therapy approaches where patient cells are edited outside the body and reinfused. As a clinical-stage company, Beam has programs in IND-enabling and Phase 1 trials and represents one of the most advanced next-generation gene editing platforms in development.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.